Tag Archives: MDCO

No Comments

CBOE Mid-Day Update 10.28.14

Volatility as an asset class The Medicines Company (MDCO) is recently up $2.94 to $25.13 after announcing the results of the pivotal Phase III clinical trial of the investigational hemostatic agent RAPLIXA, formerly known as Fibrocaps. November call option implied volatility is at 53, December is at 46, January is at 41; compared to its […]